

ASX RELEASE

18 September 2020

Results of Annual General Meeting

Amplia Therapeutics Limited (ASX: ATX) (“Amplia” or the “Company”) is pleased to confirm that each of the resolutions put to its Annual General Meeting held earlier today were passed.

Details of the results of the meeting are attached.

This ASX announcement is authorised for release by the Company Secretary.

- End -

For Further Information

Dr. John Lambert
Chief Executive Officer
john@ampliatx.com
www.ampliatx.com

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).

Results of Annual General Meeting

Name of entity

Amplia Therapeutics Limited

ABN

16 165 160 841

Date of meeting

18 September 2020

Resolutions voted on at the meeting – determined by Proxies Received					If decided by poll					Proxies received			
No	Resolution Short description	Result	Voting method	If s250U applies	Voted for		Voted against		Abstained	For	Against	Abstain	Discretion
					Number	%	Number	%	Number	Number	Number	Number	Number
2	Remuneration Report	Passed	Proxies	N/A						41,243,847	307,431	897,100	2,423,996
3	Re-Election of Dr. Warwick Tong as a Director	Passed	Proxies	N/A						48,111,589	13,013	2,375,928	2,423,746
4	Re-Election of Dr. Christopher Burns as a Director	Passed	Proxies	N/A						50,452,767	13,013	34,500	2,423,996
5	Ratify Previous Allotment of 7,975,588 Shares	Passed	Proxies	N/A						31,019,250	62,287	4,757	653,996
6	Issue of Shares to Dr. Warwick Tong - Directors Fees	Passed	Proxies	N/A						48,083,008	71,087	2,346,185	2,423,996
7	Issue of Shares to Dr. Robert Peach - Directors Fees	Passed	Proxies	N/A						49,424,436	71,087	1,004,757	2,423,996
8	Issue of Shares to Dr. Christopher Burns - Directors Fees	Passed	Proxies	N/A						48,132,487	71,087	4,757	2,440,708
9	Issue of Shares to Mr. Andrew Cooke - Directors Fees	Passed	Proxies	N/A						49,544,436	71,087	884,757	2,423,996
10	Extra 10% Placement Capacity	Passed	Proxies	N/A						50,440,541	50,149	9,590	2,423,996